The full results from the ANCHOR-1 and ANCHOR-2 studies will be presented at an upcoming scientific conference. More on GSK's Depemokimab Development Plans Earlier this year, two phase III studies ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK plc announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications. The proposed indications are as add ...

The trials met their primary endpoints, demonstrating significant improvements in nasal polyp size and obstruction with twice-yearly dosing of depemokimab compared to placebo. The findings ...

(Alliance News) - GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application for depemokimab in two indications - for asthma with type 2 ...

GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application fo ... Subscribe now to see this Premium News article from Alliance News ...